{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:48:39Z","timestamp":1792806519936,"version":"4.5.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.metabol.2017.09.016","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T19:01:10Z","timestamp":1507834870000},"page":"33-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":370,"special_numbering":"C","title":["Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences"],"prefix":"10.1016","volume":"86","author":[{"given":"Panagiotis","family":"Anagnostis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil C.","family":"Tarlatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Kauffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2017.09.016_bb0005","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-14-0253","article-title":"The polycystic ovary syndrome: a position statement from the European Society of Endocrinology","volume":"171","author":"Conway","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0010","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1701-2163(16)32915-2","article-title":"Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies","volume":"30","author":"Lujan","year":"2008","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.metabol.2017.09.016_bb0020","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1210\/jc.2010-0202","article-title":"The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance","volume":"95","author":"Johnstone","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0025","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/humupd\/dmt061","article-title":"Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society","volume":"20","author":"Dewailly","year":"2014","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.metabol.2017.09.016_bb0030","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2017.09.016_bb0035","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.09.016_bb0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrendo.2010.217","article-title":"Polycystic ovary syndrome: etiology, pathogenesis and diagnosis","volume":"7","author":"Goodarzi","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0045","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/humrep\/dei009","article-title":"Birth weight in offspring of mothers with polycystic ovarian syndrome","volume":"20","author":"Sir-Petermann","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.09.016_bb0050","doi-asserted-by":"crossref","first-page":"e0122050","DOI":"10.1371\/journal.pone.0122050","article-title":"Birth weight and polycystic ovary syndrome in adult life: is there a causal link?","volume":"10","author":"Paschou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2017.09.016_bb0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bpobgyn.2016.04.002","article-title":"Genetic studies on polycystic ovary syndrome","volume":"37","author":"Zhao","year":"2016","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0060","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1210\/er.2012-1003","article-title":"Cardiometabolic aspects of the polycystic ovary syndrome","volume":"33","author":"Randeva","year":"2012","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2017.09.016_bb0065","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/humrep\/dew243","article-title":"Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies","volume":"31","author":"Cassar","year":"2016","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.09.016_bb0070","doi-asserted-by":"crossref","first-page":"493.e1","DOI":"10.1016\/j.ajog.2017.01.003","article-title":"Reproductive Medicine Network. Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype","volume":"216","author":"Engmann","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0075","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-2265.2007.02954.x","article-title":"Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS","volume":"67","author":"Diamanti-Kandarakis","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2017.09.016_bb0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/humrep\/der418","article-title":"Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study","volume":"27","author":"Panidis","year":"2012","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.09.016_bb0085","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1530\/EC-17-0239","article-title":"Adrenal hyperandrogenism does not deteriorate insulin resistance and lipid profile in women with PCOS","volume":"6","author":"Paschou","year":"2017","journal-title":"Endocr Connect"},{"key":"10.1016\/j.metabol.2017.09.016_bb0090","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications","volume":"33","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2017.09.016_bb0095","first-page":"165","article-title":"Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women","volume":"84","author":"Legro","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0100","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2337\/db11-1360","article-title":"Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study","volume":"61","author":"Gambineri","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2017.09.016_bb0105","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/humupd\/dmq001","article-title":"Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"16","author":"Moran","year":"2010","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.metabol.2017.09.016_bb0110","article-title":"Letter to the Editor: Development and risk factors of type 2 diabetes in a nation-wide population of women with polycystic ovary syndrome","author":"Livadas","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.metabol.2017.09.016_bb0115","doi-asserted-by":"crossref","first-page":"e4863","DOI":"10.1097\/MD.0000000000004863","article-title":"Association between polycystic ovary syndrome and the risk of pregnancy complications: a PRISMA-compliant systematic review and meta-analysis","volume":"95","author":"Yu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.metabol.2017.09.016_bb0120","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1399-5448.2012.00902.x","article-title":"Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI","volume":"14","author":"Flannery","year":"2013","journal-title":"Pediatr Diabetes"},{"issue":"1","key":"10.1016\/j.metabol.2017.09.016_bb0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2017.09.016_bb0130","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0002-9343(01)00948-2","article-title":"Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome","volume":"111","author":"Legro","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.metabol.2017.09.016_bb0135","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jcem-61-5-946","article-title":"Lipoprotein lipid concentration and cardiovascular risk in women with polycystic ovary syndrome","volume":"61","author":"Wild","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0140","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/09513590400027265","article-title":"Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome","volume":"20","author":"Yilmaz","year":"2005","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0145","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1365-2265.2001.01228.x","article-title":"Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters","volume":"54","author":"Pirwany","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2017.09.016_bb0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/eje.1.02187","article-title":"Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS","volume":"155","author":"Macut","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0155","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1152\/physrev.00024.2006","article-title":"Disordered lipid metabolism and the pathogenesis of insulin resistance","volume":"87","author":"Savage","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.metabol.2017.09.016_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2010.12.027","article-title":"Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis","volume":"95","author":"Wild","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2017.09.016_bb0165","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1742-1241.2008.01897.x","article-title":"Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome","volume":"63","author":"Berneis","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.metabol.2017.09.016_bb0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF03345564","article-title":"Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome","volume":"31","author":"Essah","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.metabol.2017.09.016_bb0175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2265.1990.tb00472.x","article-title":"The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women","volume":"33","author":"Graf","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2017.09.016_bb0180","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2017.09.016_bb0185","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/DMSO.S34220","article-title":"Predicting cardiometabolic risk: waist-to-height ratio or BMI. A meta-analysis","volume":"6","author":"Savva","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.metabol.2017.09.016_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/obe.2007.0019","article-title":"Obesity and polycystic ovary syndrome","volume":"3","author":"Sam","year":"2007","journal-title":"Obes Manag"},{"key":"10.1016\/j.metabol.2017.09.016_bb0195","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/humupd\/dms030","article-title":"Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"18","author":"Lim","year":"2012","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.metabol.2017.09.016_bb0200","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajpa.10364","article-title":"Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women","volume":"124","author":"Horejsi","year":"2004","journal-title":"Am J Phys Anthropol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0205","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1177\/153537020322800610","article-title":"Subcutaneous adipose tissue pattern in lean and obese women with polycystic ovary syndrome","volume":"228","author":"Tafeit","year":"2003","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.metabol.2017.09.016_bb0210","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1001\/archinte.166.19.2081","article-title":"Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women","volume":"166","author":"Alvarez-Blasco","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.metabol.2017.09.016_bb0215","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/2230-8210.91195","article-title":"Metabolic syndrome in the Mediterranean region: current status","volume":"16","author":"Anagnostis","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0220","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1185\/03007991003590597","article-title":"Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population","volume":"26","author":"Athyros","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.metabol.2017.09.016_bb0225","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF03345554","article-title":"The metabolic syndrome in polycystic ovary syndrome","volume":"29","author":"Essah","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.metabol.2017.09.016_bb0230","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0026-0495(03)00104-5","article-title":"Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome","volume":"52","author":"Glueck","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.09.016_bb0235","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/EJE-15-0275","article-title":"Mechanisms in endocrinology: metabolic syndrome through the female life cycle","volume":"173","author":"Vryonidou","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0240","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3109\/09513590.2011.613968","article-title":"Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset","volume":"28","author":"Espin\u00f3s-G\u00f3mez","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0245","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/cen.12008","article-title":"Prevalence of metabolic syndrome in women with polycystic ovary syndrome","volume":"78","author":"Panidis","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2017.09.016_bb0250","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1210\/jc.2002-021816","article-title":"Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome","volume":"88","author":"Orio","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0255","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/09513590400002300","article-title":"Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome","volume":"19","author":"Hirschberg","year":"2004","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0260","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/09513590600847421","article-title":"Polycystic ovary syndrome in bulimic women\u2013an evaluation based on the new diagnostic criteria","volume":"22","author":"Naess\u00e9n","year":"2006","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0265","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1210\/jc.2003-031583","article-title":"Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition","volume":"89","author":"Moran","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0270","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/humrep\/den433","article-title":"Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria","volume":"24","author":"Goverde","year":"2009","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.09.016_bb0275","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1471-0528.2009.02347.x","article-title":"Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population","volume":"116","author":"Zhang","year":"2009","journal-title":"BJOG"},{"key":"10.1016\/j.metabol.2017.09.016_bb0280","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1172\/JCI57132","article-title":"Inflammatory links between obesity and metabolic disease","volume":"121","author":"Lumeng","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2017.09.016_bb0285","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0026-0495(99)90100-2","article-title":"Elevated serum levels of tumor necrosis factor in normal-weight women with polycystic ovary syndrome","volume":"48","author":"Gonzalez","year":"1999","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.09.016_bb0290","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.metabol.2017.02.012","article-title":"Metabolic syndrome enhances endoplasmic reticulum, oxidative stress and leukocyte-endothelium interactions in PCOS","volume":"71","author":"Ba\u00f1uls","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.09.016_bb0295","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1210\/jc.2003-031365","article-title":"Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity","volume":"89","author":"Escobar-Morreale","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0300","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1210\/jc.2007-1343","article-title":"Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis","volume":"92","author":"Shroff","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0305","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/01443615.2016.1256966","article-title":"The effects of IL-1A and IL-6 genes polymorphisms on gene expressions, hormonal and biochemical parameters in polycystic ovary syndrome","volume":"37","author":"Eser","year":"2017","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0310","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1210\/jc.2003-031096","article-title":"Blumenfeld Z' Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease","volume":"89","author":"Boulman","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0315","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.09.016_bb0320","doi-asserted-by":"crossref","first-page":"R219","DOI":"10.1530\/REP-14-0435","article-title":"Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome","volume":"149","author":"Spritzer","year":"2015","journal-title":"Reproduction"},{"key":"10.1016\/j.metabol.2017.09.016_bb0325","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/138945010790030992","article-title":"Should adipokines be considered in the choice of the treatment of obesity-related health problems?","volume":"11","author":"Athyros","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.metabol.2017.09.016_bb0330","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/humupd\/dmp006","article-title":"Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis","volume":"15","author":"Toulis","year":"2009","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.metabol.2017.09.016_bb0335","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3109\/09513590.2010.508543","article-title":"Association of the T45G and G276T polymorphisms in the adiponectin gene with PCOS: a meta-analysis","volume":"28","author":"Gao","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0340","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/1933719116670265","article-title":"Leptin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis","volume":"24","author":"Zheng","year":"2017","journal-title":"Reprod Sci"},{"key":"10.1016\/j.metabol.2017.09.016_bb0345","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jcem.86.8.7775","article-title":"Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome","volume":"86","author":"Veldhuis","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0350","first-page":"1","article-title":"Serum visfatin, vascular endothelial growth factor and matrix metalloproteinase-9 in women with polycystic ovary syndrome","author":"Dambala","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0355","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3109\/09513590.2015.1056140","article-title":"High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis","volume":"31","author":"Sun","year":"2015","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0360","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/09513590.2016.1254180","article-title":"Circulating omentin-1 levels in women with polycystic ovary syndrome: a meta-analysis","volume":"33","author":"Tang","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0365","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.metabol.2015.12.009","article-title":"Nonalcoholic fatty future disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.09.016_bb0370","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1665-2681(19)31616-3","article-title":"Prevalence of non-alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens","volume":"9","author":"Gutierrez-Grobe","year":"2010","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0375","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1440-1746.2008.05740.x","article-title":"An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome","volume":"24","author":"Brzozowska","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0380","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/humrep\/dew076","article-title":"Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome","volume":"31","author":"Macut","year":"2016","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.09.016_bb0385","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-017-0708-9","article-title":"Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis","author":"Rocha","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.metabol.2017.09.016_bb0390","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1210\/jc.2012-1382","article-title":"Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance","volume":"97","author":"Jones","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0395","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/00365521.2010.539251","article-title":"Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS)","volume":"46","author":"Hossain","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0400","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejogrb.2013.11.011","article-title":"Hypertension in women with polycystic ovary syndrome: prevalence and associated cardiovascular risk factors","volume":"173","author":"Shi","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0405","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/humrep\/16.3.556","article-title":"Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population","volume":"16","author":"Elting","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.09.016_bb0410","first-page":"21","article-title":"Role of 24-hour monitoring in assessing blood pressure changes in polycystic ovary syndrome","volume":"45","author":"Orbetzova","year":"2003","journal-title":"Folia Med (Plovdiv)"},{"key":"10.1016\/j.metabol.2017.09.016_bb0415","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/oxfordjournals.humrep.a019028","article-title":"Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?","volume":"11","author":"Holte","year":"1996","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.09.016_bb0420","first-page":"508","article-title":"Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance","volume":"75","author":"Zimmermann","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0425","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1210\/jc.2011-1677","article-title":"Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study","volume":"96","author":"Schmidt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0430","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1210\/jc.2006-0399","article-title":"Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome","volume":"91","author":"Cascella","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0435","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.fertnstert.2016.12.017","article-title":"Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life","volume":"107","author":"Pinola","year":"2017","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2017.09.016_bb0440","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1210\/jc.2010-2279","article-title":"Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome","volume":"96","author":"Manner\u00e5s-Holm","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0445","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/jcem.87.8.8716","article-title":"Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state","volume":"87","author":"Yildiz","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0450","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1046\/j.1365-2265.2000.00946.x","article-title":"Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS)","volume":"52","author":"Atiomo","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2017.09.016_bb0455","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0015-0282(00)01614-9","article-title":"Are women with polycystic ovary syndrome resistant to activated protein C?","volume":"74","author":"Atiomo","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2017.09.016_bb0460","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/humrep\/17.2.314","article-title":"Polycystic ovarian syndrome and thrombophilia","volume":"17","author":"Tsanadis","year":"2002","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.09.016_bb0465","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/humrep\/deg190","article-title":"Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine","volume":"18","author":"Schachter","year":"2003","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.09.016_bb0470","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1210\/jc.2013-2374","article-title":"Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis","volume":"98","author":"Domecq","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0475","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1210\/jc.2014-3196","article-title":"Approach to the patient: contraception in women with polycystic ovary syndrome","volume":"100","author":"Yildiz","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0480","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jpag.2016.06.010","article-title":"Does the oral contraceptive pill increase plasma intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and tumor necrosis factor-\u03b1 levels in women with polycystic ovary syndrome: a pilot study","volume":"30","author":"Yousuf","year":"2017","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0485","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001\u20139","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2017.09.016_bb0490","first-page":"713","article-title":"Insulin resistance and cardiovascular disease","volume":"86","author":"McFarlane","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0495","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(11)60105-0","article-title":"Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies","volume":"377","author":"Wormser","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2017.09.016_bb0500","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1210\/jc.2003-032237","article-title":"Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome","volume":"89","author":"Talbott","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0505","doi-asserted-by":"crossref","first-page":"356.e1","DOI":"10.1016\/j.amjmed.2005.10.059","article-title":"Endothelial dysfunction in PCOS: role of obesity and adipose hormones","volume":"119","author":"Carmina","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.metabol.2017.09.016_bb0510","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1210\/jc.2004-2363","article-title":"Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome","volume":"90","author":"Vryonidou","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0515","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1210\/jc.2005-0151","article-title":"Predictors of endothelial dysfunction in young women with polycystic ovary syndrome","volume":"90","author":"Kravariti","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0520","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1097\/HJH.0b013e3283630362","article-title":"Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a polycystic ovary syndrome phenotype","volume":"31","author":"Armeni","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2017.09.016_bb0525","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/humupd\/dmr046","article-title":"Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"18","author":"Meyer","year":"2012","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.metabol.2017.09.016_bb0530","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2265.2012.04490.x","article-title":"Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies","volume":"78","author":"Sprung","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2017.09.016_bb0535","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.thromres.2015.10.022","article-title":"Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome","volume":"136","author":"Okoroh","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.metabol.2017.09.016_bb0540","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1210\/jc.2014-3886","article-title":"The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage","volume":"100","author":"Hart","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0545","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0895-4356(98)00035-3","article-title":"Mortality of women with polycystic ovary syndrome at long-term follow-up","volume":"51","author":"Pierpoint","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.metabol.2017.09.016_bb0550","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2265.2000.01000.x","article-title":"Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study","volume":"52","author":"Wild","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2017.09.016_bb0555","first-page":"74","article-title":"Risk of cardiovascular events in patients with polycystic ovary syndrome","volume":"70","author":"Iftikhar","year":"2012","journal-title":"Neth J Med"},{"key":"10.1016\/j.metabol.2017.09.016_bb0560","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/cen.12068","article-title":"Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study","volume":"78","author":"Mani","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2017.09.016_bb0565","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1089\/jwh.2015.5441","article-title":"Cardiovascular disease and 10-year mortality in postmenopausal women with clinical features of polycystic ovary syndrome","volume":"25","author":"Merz","year":"2016","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.metabol.2017.09.016_bb0570","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1210\/jc.2010-1709","article-title":"Menstrual irregularity and cardiovascular mortality","volume":"96","author":"Wang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0575","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1210\/jcem.87.5.8471","article-title":"Menstrual cycle irregularity and risk for future cardiovascular disease","volume":"87","author":"Solomon","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.09.016_bb0580","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/humupd\/dmr001","article-title":"PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis","volume":"17","author":"de Groot","year":"2011","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.metabol.2017.09.016_bb0585","doi-asserted-by":"crossref","first-page":"33715","DOI":"10.18632\/oncotarget.9553","article-title":"Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517302743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517302743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:20:39Z","timestamp":1758428439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049517302743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":117,"alternative-id":["S0026049517302743"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2017.09.016","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2017.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}